Brain Metastases FDA Approvals, Pipeline Report, Emerging Drugs, and Clinical Trials 2024 (Updated)

DelveInsight's, "Brain Metastases Pipeline Insight 2024" report provides comprehensive insights about 40+ Brain Metastases companies and 45+ pipeline drugs in the Brain Metastases pipeline landscape. It covers the Brain Metastases pipeline drug profiles, including clinical and nonclinical stage products. Brain Metastases pipeline report also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Key Takeaways from the Brain Metastases Pipeline Report
• DelveInsight's Brain Metastases pipeline report depicts a robust space with 40+ active players working to develop 45+ pipeline therapies for Brain Metastases treatment.
• The leading companies working in the Brain Metastases Market include HUYA Bioscience, Kazia Therapeutics, BioMimetix, EpicentRx, Inc., Angiochem, Medolution Ltd., Betta Pharmaceuticals Co., Ltd., Merck Sharp & Dohme LLC, Bristol-Myers Squibb, 2-BBB Medicines, DEKK-TEC, Inc., Nascent Biotech, Quadriga Biosciences, Inc., Jubilant Therapeutics, Denali Therapeutics Inc, NUVATION BIO, Novocure GmbH, Affinia Therapeutics, Specialised Therapeutics, Precirix, Ashvattha Therapeutics, Cereius, Allarity Therapeutics, TYK Medicine, Surgimab, ORIC Pharmaceuticals, SonALAsense, Nerviano Medical Sciences, Lin Bioscience, Inc., Zai Lab, Lantern Pharma, ABM Therapeutics, Carthera, and others.
• Promising Brain Metastases Pipeline Therapies in the various stages of development include 8F fluciclovine, BT-M01, RRx-001 + WBRT, BMX-001, Veliparib, ANG1005, Keynatinib, and others.
• May 2024:- GT Medical Technologies Inc.- A Phase 3 Randomized Controlled Trial of Post-Surgical Stereotactic Radiotherapy (SRT) Versus Surgically Targeted Radiation Therapy (STaRT) With Gamma Tile for Treatment of Newly Diagnosed Metastatic Brain Tumors.
• April 2024: Colette Shen announced a study of Phase 1 & 2 clinical trials for Olaparib and Durvalumab. This study is a Phase I/II study evaluating the safety and effectiveness of focused radiation therapy (radiosurgery) together with olaparib, followed by immunotherapy, for patients with brain metastases from triple negative or BRCA-mutated breast cancers.
• March 2024: University of Wisconsin, Madison announced a study of Phase 3 clinical trials for F-Fluciclovine radiotracer. The purpose of this research is to utilize new imaging methods to aid in assessing whether imaging shows presence of tumor. Developing imaging technologies is critical for more accurately identifying location and amount of tumor, which will then lead to improvements in future cancer therapy.

Request a sample and discover the recent advances in Brain Metastases Treatment Drugs @ Brain Metastases Pipeline Outlook Report- https://www.delveinsight.com/sample-request/brain-metastases-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

In the Brain Metastases pipeline report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Brain metastases collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Brain Metastases Overview
Brain metastases are a common complication of cancer and the most common type of brain tumor. Anywhere from 10% to 26% of patients who die from their cancer will develop brain metastases. While few cancers that metastasize to the brain can be cured using conventional therapies, long-term survival and palliation are possible with minimal adverse effects to patients. Increasingly, neuro-cognition and quality of life are being recognized as important endpoints for patients as survival continues to increase.

Find out more about Brain Metastases Therapeutics Assessment @ Brain Metastases Preclinical and Discovery Stage Products- https://www.delveinsight.com/sample-request/brain-metastases-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Brain Metastases Emerging Drugs Profile

ANG1005: Angiochem
ANG1005 is a novel targeted taxane derivative that is the first oncology product to leverage Angiochem's technology platform to cross the blood-brain barrier (BBB) and enter cancer cells. ANG1005 is an Angiopep-2 paclitaxel conjugate that gains entry into the brain by targeting the LRP-1, which is one of the most highly-expressed receptors on the surface of the BBB. Once inside the brain, ANG1005 enters tumor cells using the same receptor-mediated pathway through LRP-1, which is upregulated in various cancer cells including malignant glioma and metastatic cancers in the brain.
A Phase II, multi-center, open label study has been conducted with ANG1005 in patients with brain metastases from breast cancer (NCT01480583). The anticancer activity of ANG1005 was extremely encouraging and 2 additional Phase II trials have been conducted to further confirm its clinical activity in patients with recurrent high grade glioma (NCT01967810) and breast cancer patients with recurrent brain metastases (NCT02048059) and the drug is currently investigated in Phase III trials.

Azeliragon: Cantex Pharmaceuticals, Inc.
Azeliragon, is an oral, small molecule, administered once-daily, that inhibits RAGE interactions with its natural ligands, including HMGB1 and S100 proteins, in the tumor microenvironment. Activation of RAGE by these ligands stimulates cancer and its progression and metastasis and resistance to cancer treatment.
Azeliragon was licensed in mid-2021 from vTv Therapeutics Inc. and was originally in development by vTv for Alzheimer's disease. There has been extensive demonstration of pre-clinical efficacy of RAGE inhibition in animal models of several cancers, including pancreatic cancer, glioblastoma, and brain metastasis from breast and lung cancer, as well as diverse serious complications of cancer, including cancer-related cognitive decline, as well as the development of metastatic disease. The drug is currently investigated in Phase I/II clinical trials for brain metastases.

AZD3759: Alpha Biopharma Ltd.
Zorifertinib (AZD3759) is a type of reversible new generation EGFR TKI, which has a strong ability to penetrate the bloodstream, cerebrospinal fluid, and can reach blood volume in the tissue. It is currently investigated for brain metastases and completed Phase II/III trial in July 2022.

Brain Metastases Pipeline Therapeutics Assessment
There are approx. 45+ key companies which are developing the therapies for Brain metastases. The Brain Metastases companies which have their Brain metastases drug candidates in the most advanced stage, i.e. phase III.

DelveInsight's Brain Metastases Pipeline Report covers around 45+ products under different phases of clinical development like
• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Brain metastases pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
• Intra-articular
• Intraocular
• Intrathecal
• Intravenous
• Ophthalmic
• Oral
• Parenteral
• Subcutaneous
• Topical
• Transdermal

Brain Metastases Products have been categorized under various Molecule types such as
• Oligonucleotide
• Peptide
• Small molecule

Learn more about the emerging Brain Metastases Pipeline Therapies @ Brain Metastases Clinical Trials Assessment- https://www.delveinsight.com/sample-request/brain-metastases-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Scope of the Brain Metastases Pipeline Report
• Coverage- Global
• Brain Metastases Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Brain Metastases Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
• Brain Metastases Companies- HUYA Bioscience, Kazia Therapeutics, BioMimetix, EpicentRx, Inc., Angiochem, Medolution Ltd., Betta Pharmaceuticals Co., Ltd., Merck Sharp & Dohme LLC, Bristol-Myers Squibb, 2-BBB Medicines, DEKK-TEC, Inc., Nascent Biotech, Quadriga Biosciences, Inc., Jubilant Therapeutics, Denali Therapeutics Inc, NUVATION BIO, Novocure GmbH, Affinia Therapeutics, Specialised Therapeutics, Precirix, Ashvattha Therapeutics, Cereius, Allarity Therapeutics, TYK Medicine, Surgimab, ORIC Pharmaceuticals, SonALAsense, Nerviano Medical Sciences, Lin Bioscience, Inc., Zai Lab, Lantern Pharma, ABM Therapeutics, Carthera, and others.
• Brain Metastases Pipeline Therapies- 8F fluciclovine, BT-M01, RRx-001 + WBRT, BMX-001, Veliparib, ANG1005, Keynatinib, and others.

Dive deep into rich insights for new drugs for Brain Metastases Treatment, Visit @ Brain Metastases Market Drivers and Barriers, and Future Perspective- https://www.delveinsight.com/sample-request/brain-metastases-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Table of Content
1. Introduction
2. Executive Summary
3. Brain metastases: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Brain metastases- DelveInsight's Analytical Perspective
7. Late Stage Products (Phase III)
8. ANG1005: Angiochem
9. Drug profiles in the detailed report…..
10. Mid Stage Products (Phase II)
11. Paxalisib: Kazia Therapeutics
12. Drug profiles in the detailed report…..
13. Early Stage Products (Phase I)
14. MW151: ImmunoChem Therapeutics, LLC
15. Drug profiles in the detailed report…..
16. Preclinical and Discovery Stage Products
17. JBI-2174: Jubilant Therapeutics
18. Drug profiles in the detailed report…..
19. Inactive Products
20. Brain metastases Key Companies
21. Brain metastases Key Products
22. Brain metastases- Unmet Needs
23. Brain metastases- Market Drivers and Barriers
24. Brain metastases- Future Perspectives and Conclusion
25. Brain metastases Analyst Views
26. Brain metastases Key Companies
27. Appendix

For further information on the Brain Metastases Pipeline therapeutics, reach out to Brain Metastases Unmet Needs and Analyst Views- https://www.delveinsight.com/sample-request/brain-metastases-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

List of Important Links-
Uveitis Market- https://www.delveinsight.com/report-store/uveitis-market
Hidradenitis Suppurativa Market- https://www.delveinsight.com/report-store/hidradenitis-suppurativa-market
Peripheral T-cell Lymphoma Market- https://www.delveinsight.com/report-store/peripheral-t-cell-lymphoma-ptcl-market
Glaucoma Market- https://www.delveinsight.com/report-store/glaucoma-market
Retinitis Pigmentosa Market- https://www.delveinsight.com/report-store/retinitis-pigmentosa-market
Oropharyngeal Cancer Market- https://www.delveinsight.com/report-store/oropharyngeal-cancer-market
Thyroid Cancer Market- https://www.delveinsight.com/report-store/thyroid-cancer-market
Paranasal Sinus Cancer Market- https://www.delveinsight.com/report-store/paranasal-sinus-cancer-market
Castration-resistant Prostate Cancer Market- https://www.delveinsight.com/report-store/castration-resistant-prostate-cancer-crpc-market
Opioid Withdrawal Syndrome Market- https://www.delveinsight.com/report-store/opioid-withdrawal-syndrome-market
Complicated Urinary Tract Infections Market- https://www.delveinsight.com/report-store/complicated-urinary-tract-infections-market
Cervical Dystonia Market- https://www.delveinsight.com/report-store/cervical-dystonia-market
Schizophrenia Market- https://www.delveinsight.com/report-store/schizophrenia-market-insight
Focal Segmental Glomerulosclerosis Market- https://www.delveinsight.com/report-store/focal-segmental-glomerulosclerosis-fsgs-market
Obstructive Sleep Apnea Market- https://www.delveinsight.com/report-store/obstructive-sleep-apnea-osa-market
Severe Hypertriglyceridemia Market- https://www.delveinsight.com/report-store/severe-hypertriglyceridemia-shtg-market
Short Bowel Syndrome Market- https://www.delveinsight.com/report-store/short-bowel-syndrome-market
Complement 3 Glomerulopathy Market- https://www.delveinsight.com/report-store/complement-3-glomerulopathy-c3g-market
Aplastic Anemia Market- https://www.delveinsight.com/report-store/aplastic-anemia-market
Nephrotic Syndrome Market- https://www.delveinsight.com/report-store/nephrotic-syndrome-market
Pulmonary Arterial Hypertension Market- https://www.delveinsight.com/report-store/pulmonary-arterial-hypertension-market
Hemophilia A Market- https://www.delveinsight.com/report-store/hemophilia-a2030-market
Complicated Urinary Tract Infections Market- https://www.delveinsight.com/report-store/complicated-urinary-tract-infections-market

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: info@delveinsight.com
Phone: 9650213330
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

This release was published on openPR.